Narcolepsy Treatment Market 2020 Analysis, Growth, Share, Trends | Leading Players - BIOPROJET, Hikma Pharmaceuticals, Teva Pharmaceuticals, Novartis, Mylan, Alkem Labs, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Vallon Pharmaceuticals 

Global Narcolepsy Treatment Market report consists of a market overview and the growth prospects of the market. These predictions feature important inputs from leading industry experts & underline every statistical detail regarding the market. The current environment of the industry and the key trends shaping the market are presented in the report. Insightful predictions for the coming few years have also been taken into consideration in this business research study. This Narcolepsy Treatment Market research report suggests that the market is growing at a very fast pace and with the rise in technological innovation, competition and M&A activities in the business many local and regional vendors are offering specific application products for varied end-users.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-narcolepsy-treatment-market&rp

Market Analysis: Global Narcolepsy Treatment Market

Global narcolepsy treatment market is expected to grow at a healthy CAGR in the forecast period of 2019-2026. Increase in demand of targeted mode of therapies and high unmet need of treatment are the key factors for growth of this market

Key Market Players:

Few of the major competitors currently working in the global narcolepsy treatment market are Vallon Pharmaceuticals Inc, AVADEL PHARMACEUTICALS, PLC, Jazz Pharmaceuticals plc, BIOPROJET, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Novartis AG, Mylan N.V., Jubilant Life Sciences Ltd, Amneal Pharmaceuticals LLC, Alkem Labs, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd, Zydus Cadila, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc and others

Get Full TOC, Tables and Figures of Market Report @ https://www.databridgemarketresearch.com/toc/?dbmr=global-narcolepsy-treatment-market&rp

Market Definition: Global Narcolepsy Treatment Market

Narcolepsy is a neurological disorders characterized by excessive daytime sleepiness, and the inability to regulate sleep-wake cycles normally. People with narcolepsy fall into REM sleep immediately after falling asleep and experience extremely sleepy during the day and interference with normal activities, cloudy and lapse in the memory, extreme exhaustion and concentration problem as well as feeling of depression.

According to the statistics published in the National Institute of Neurological Disorders and Stroke, an estimated annual prevalence of narcolepsy is approximately 135,000 to 200,000 people in the United States. Presence of refined healthcare infrastructure and high demand of disease specific novel therapies are the key factors that fueling the market growth

Segmentation: Global Narcolepsy Treatment Market

Narcolepsy Treatment Market : By Type

Type 1 Narcolepsy
Type 2 Narcolepsy

Narcolepsy Treatment Market : By Drugs

Selective Histamine H3-Receptor Antagonist
Stimulants
Serotonin Reuptake Inhibitors
Tricyclic Antidepressants
Central Nervous System Depressant
Others

Narcolepsy Treatment Market : By Route of Administration

Oral
Injectable

Narcolepsy Treatment Market : By End Users

Hospitals
Homecare
Specialty Clinics
Others

Narcolepsy Treatment Market : By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

Narcolepsy Treatment Market : By Geography

North America
South America
Europe
Asia-Pacific
Middle East & Africa

Key Developments in the Market:

In January 2018, AVADEL PHARMACEUTICALS, PLC received an Orphan Drug Designation from the FDA for FT 218, a once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy.

In October 2017, Harmony Biosciences, LLC, has acquired the exclusive US right to develop, register and commercialize pitolisant, a selective histamine H3-receptor antagonist from BIOPROJET for the treatment of narcolepsy in adult patients with and without cataplexy. The acquistion of pitolisant, enables the company to accelerate the ability to address unmet needs for patients suffering from sleep and other central nervous system disorders.

Narcolepsy Treatment Market Drivers :

Growing prevalence of narcolepsy worldwide is drive the market growth
The competitive scenario of market and strategic collaborations may boost the market position
Huge financial support to the researchers for developing novel intervention is boosting the market growth
High demand of disease specific novel treatment can also act as a market driver

Narcolepsy Treatment Market Restraints :

The high cost diagnosis and treatment of disease and unfavorable reimbursement scenario are expected to limit market growth
Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market

Reasons to Purchase this Report :

Current and future of global narcolepsy treatment market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-narcolepsy-treatment-market&rp

Contact Us
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Mail: Corporatesales@databridgemarketresearch.com
https://databridgemarketresearch.com

About Data Bridge Market Research :

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.